Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

First-line chemo-free MCL combo is durable

Ruan J et al. Blood. 2018 Sep 4. doi: 10.1182/blood-2018-07-859769.

Key clinical point: Lenalidomide/rituximab induction and maintenance is an effective outpatient regimen for mantle cell lymphoma patients.

Major finding: After 64-months of median follow-up, 21 of 33 patients with initial responses remained in remission.

Study details: Five-year follow-up of a phase 2 single-arm trial of lenalidomide/rituximab induction and maintenance in 38 patients with mantle cell lymphoma.

Disclosures: The study was supported in part by Celgene Corporation, a Clinical Translational Science Center grant, and the Lymphoma Foundation. Dr. Ruan has received research support and been a consultant for Celgene, and other coauthors reported research support and consultant relationships with the company.

Read the article.


Ruan J et al. Blood. 2018 Sep 4. doi : 10.1182/blood-2018-07-859769.

Must Reads in Aggressive Lymphomas

Researchers characterize new subtype of high-grade DLBCL, 3 articles from the Journal of Clinical Oncology

Patient perspectives on NHL treatment, Chircop D et al. Eur J Oncol Nurs. 2018 Aug;35:117-21

Corticosteroid use poses risk of febrile neutropenia, Chao CR et al. J Natl Compr Canc Netw. 2018;16(10):1201-8

5F9 plus rituximab looks durable in NHL, Advani R et al. N Engl J Med. 2018;379:1711-21

Age is an independent predictor of mortality after transplant, Kyriakou C et al. Biol Blood Marrow Transplant. 2018 Sep 13. doi: 10.1016/j.bbmt.2018.08.025